Progyny (PGNY) Investor Day 2024 summary
Event summary combining transcript, slides, and related documents.
Investor Day 2024 summary
9 Jul, 2026Strategic vision and business fundamentals
Positioned for significant growth by expanding from fertility into broader women's health, including maternity and menopause, targeting overlooked and underfunded areas of healthcare.
Maintains strong fundamentals: high client retention, member satisfaction, profitability, scalability, and margin expansion, with 99% retention by lives and 80+ NPS.
Plans to double revenue and 2.5x Adjusted EBITDA by 2028, targeting $2.4B+ revenue, $500M+ Adjusted EBITDA, 20% revenue CAGR, and 25% Adjusted EBITDA CAGR.
Growth levers include deeper penetration of existing clients, new client acquisition, TAM expansion into smaller and global markets, and new product launches.
Multi-year targets are underpinned by a robust client base, expanding product suite, disciplined financial management, and strategic investments in women's health.
Product innovation and expansion
Expanded offerings from fertility to maternity, menopause, pregnancy, postpartum, and other women's health areas, leveraging a platform built for personalized, evidence-based care.
New products are designed to address gaps in care, improve outcomes, and reduce costs, with a focus on member experience and provider enablement.
Product roadmap includes further expansion into parenting, sexual and pelvic health, and other clinical adjacencies.
New products are expected to contribute 8%-10% of revenue by 2028, with higher gross margins than core fertility services.
Case rate-based revenue models are being piloted for new services, with significant client interest and early adoption.
Go-to-market and client relationships
Diversified go-to-market approach: direct sales, client success-driven upsell, consultant engagement, and partnerships with aggregators, health plans, and benefit consultants.
Near 100% client retention, 80%+ client NPS, and 40% of clients actively advocating for the benefit.
High pharmacy attachment rates (93%) and growing adoption of new products (15% attachment rate), with ongoing upsell opportunities.
Expansion into smaller employer segments, federal, Taft-Hartley, and global markets, leveraging partnerships and tailored distribution models.
Clients report improved outcomes, cost savings, and enhanced employee satisfaction, supporting talent attraction and retention.
Latest events from Progyny
- Record Q1 revenue, double-digit EBITDA growth, and raised guidance amid strong demand.PGNY
Q1 20259 Jul 2026 - Record revenue, strong retention, and all proposals approved; poised for growth in 2026.PGNY
AGM 202621 May 2026 - Robust demand, high retention, and product expansion position the business for sustained growth.PGNY
Bank of America Global Healthcare Conference 202613 May 2026 - Q1 revenue up 12.2% (ex-large client), net income up 61%, and 8.8M shares repurchased.PGNY
Q1 20268 May 2026 - Proxy covers director elections, auditor ratification, pay reforms, and governance changes.PGNY
Proxy filing10 Apr 2026 - Votes will address director elections, auditor ratification, and governance amendments.PGNY
Proxy filing10 Apr 2026 - Key votes include director elections, auditor ratification, and reducing supermajority voting thresholds.PGNY
Proxy filing31 Mar 2026 - Strong utilization and new product launches drive growth amid stable competition and tech investment.PGNY
2026 KeyBanc Capital Markets Healthcare Forum17 Mar 2026 - Stable growth, high retention, and new market expansion drive a positive long-term outlook.PGNY
Barclays 28th Annual Global Healthcare Conference11 Mar 2026